KENNETH RAPOZA – INDIAN DRUG COMPANY FAILS FDA INSPECTION 5 25 24

A PHARMACEUTICAL COMPANY IN INDIA RECENTLY FAILED 10 REQUIREMENTS FOR “GOOD MANUFACTURING PRACTICES” FOLLOWING INSPECTION OF THE FACILITIES BY THE FDA. SO WHAT DOES THAT MEAN FOR THE CONTINUING DRUG SHORTAGES? WE SPEAK WITH KENNETH RAPOZA, INDUSTRY ANALYST FROM THE “COALITION FOR A PROSPEROUS AMERICA” AND FORMER STAFF FOREIGN CORRESPONDENT FOR THE WALL STREET JOURNAL.